BFPET for Regional Myocardial Perfusion Imaging

Inclusion Criteria: * Subjects must provide written informed consent prior to any study related procedures; * Subjects must be ≥ 21 and ≤ 85 years of age; * Subjects must have known or suspected CAD documented by ≥2 segments of reversible perfusion abnormalities on a SPECT (MPI)study Exclusion Criteria * Any clinically significant acute or unstable physical or psychological disease judged by the investigators based on medical history or screening physical examination; * Blood pressure over 180/100mmHg * Acute changes in comparison to most recent ECG; * Recent (within 3 months) cardiac arrest, unstable angina, cerebro-vascular accident (CVA), CABG or PCI * Any pacemaker or defibrillator implanted within the last three months; * Inability to remain in camera for approximately 60 minutes * Bronchospasm * Serum creatinine \> 2 mg/dL; * Cancer patients who have received chemotherapy or radiation therapy within the past 60 days. * Any exposure to any investigational drug(s) or medical device(s) within four (4) weeks prior to imaging study; * Any physical or psychological disease judged by the investigators to be incompatible with the study, based on medical history or screening physical examination. * NYHA Class III or IV Congestive heart failure; * Subject has symptomatic hypotension * Allergic or intolerant to aminophylline, nitroglycerin or metoprolol * Allergic or intolerant to regadenoson or any of its excipients * Prior participants in the study. * Female subjects only: Positive serum and/or urine pregnancy test or is lactating or the possibility of pregnancy cannot be ruled out prior to dosing. Females not of child-bearing potential require confirmatory documentation in their medical records or must have a negative pregnancy test within 4 hours prior to receiving the test drug and agree to use an acceptable form of birth control for at least 30 days following BFPET administration.